{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-040327","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.976784+00:00","generated_at":"2026-06-08T04:48:47.565152+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Cocrystal Pharma Q3 net loss $4.2M ($0.41/sh) vs $5.7M loss year ago; cash $29.7M","bullets":["Net loss for Q3 2023 was $4.2M ($0.41 per share) compared with net loss of $5.7M ($0.70 per share) in Q3 2022.","R&D expenses increased to $4.2M from $3.9M, driven by clinical advancement of CC-42344 and CDI-988 trials.","Cash and equivalents $29.7M as of Sep 30, 2023, down from $37.1M at Dec 31, 2022; working capital $30.3M.","Enrollment underway in Phase 1 trial for dual coronavirus-norovirus oral protease inhibitor CDI-988.","Phase 2a human challenge trial for oral influenza A drug CC-42344 expected to begin dosing before year-end 2023; inhaled CC-42344 Phase 1 planned H1 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-040327","json":"https://secwatch.observer/filing/0001493152-23-040327.json","markdown":"https://secwatch.observer/filing/0001493152-23-040327.md","text":"https://secwatch.observer/filing/0001493152-23-040327.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/0001493152-23-040327-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:48:47.565152+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85a69eb62e7ee421cf209413aae3303817958ba7","claim":"Cocrystal Pharma, Inc. reported financial results for three and nine months ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, Cocrystal Pharma, Inc. (the \"Company\") issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1412486/000149315223040327/0001493152-23-040327-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three and nine months ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}